Get started
Author

Albert Chau

ORCID: 0000-0002-5141-1710
Observed ORCID: 0000-0002-5141-1710
OpenAlex ID: A5115864998
A Phase I Dose Escalation and Cohort Expansion Study of CB307, a Trispecific Humabody against PSMA, CD137, and Albumin in Patients with PSMA-Positive Solid Tumors
2025 · Johann S. de Bono, Anja Williams, et al. · Clinical Cancer Research · 8
18F-Fluciclovine for Detection of Recurrent Brain Metastases After Radiation Therapy: Image Interpretation Criteria and Diagnostic Performance From the PURSUE Study
2026 · Rupesh Kotecha, Veronica Chiang, et al. · International Journal of Radiation Oncology*Biology*Physics · 5
High-density retinal signal deciphering in support of diagnosis in psychiatric disorders: A new paradigm
2025 · Salomon Massoda, Hind Rakkay, et al. · Biomedical Signal Processing and Control · 3
How Standard of Truth Methodology Impacts Diagnostic PSMA-Targeting Radiopharmaceutical Evaluation: Learnings from the Phase 3 SPOTLIGHT Study
2025 · Benjamin H. Lowentritt, Albert Chau, et al. · Diagnostics · 1
PDF
Sparse representation of high-density retinal signal in time-frequency domain to support diagnosis in psychiatric disorders
2026 · Salomon Massoda, Claudia Émond, et al. · Intelligence-Based Medicine
Supplementary Table 1 from A Phase I Dose Escalation and Cohort Expansion Study of CB307, a Trispecific Humabody against PSMA, CD137, and Albumin in Patients with PSMA-Positive Solid Tumors
2025 · Johann S. de Bono, Anja Williams, et al.
Data from A Phase I Dose Escalation and Cohort Expansion Study of CB307, a Trispecific Humabody against PSMA, CD137, and Albumin in Patients with PSMA-Positive Solid Tumors
2025 · Johann S. de Bono, Anja Williams, et al.
Works count: 7
Citation count: 17
H-index: 3
I10-index:
Year
Topic
Type